402 related articles for article (PubMed ID: 24052547)
1. EZH2 mutations are frequent and represent an early event in follicular lymphoma.
Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J
Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547
[TBL] [Abstract][Full Text] [Related]
2. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
[TBL] [Abstract][Full Text] [Related]
3. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
[TBL] [Abstract][Full Text] [Related]
4. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
5. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.
Okosun J; Bödör C; Wang J; Araf S; Yang CY; Pan C; Boller S; Cittaro D; Bozek M; Iqbal S; Matthews J; Wrench D; Marzec J; Tawana K; Popov N; O'Riain C; O'Shea D; Carlotti E; Davies A; Lawrie CH; Matolcsy A; Calaminici M; Norton A; Byers RJ; Mein C; Stupka E; Lister TA; Lenz G; Montoto S; Gribben JG; Fan Y; Grosschedl R; Chelala C; Fitzgibbon J
Nat Genet; 2014 Feb; 46(2):176-181. PubMed ID: 24362818
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
7. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764
[TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
10. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
11. The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.
Barasch NJK; Liu YC; Ho J; Bailey N; Aggarwal N; Cook JR; Swerdlow SH
Hum Pathol; 2020 Dec; 106():93-105. PubMed ID: 33045225
[TBL] [Abstract][Full Text] [Related]
12. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.
Siddiqi IN; Friedman J; Barry-Holson KQ; Ma C; Thodima V; Kang I; Padmanabhan R; Dias LM; Kelly KR; Brynes RK; Kamalakaran S; Houldsworth J
Mod Pathol; 2016 Jun; 29(6):570-81. PubMed ID: 26965583
[TBL] [Abstract][Full Text] [Related]
14. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
15. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R
Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756
[TBL] [Abstract][Full Text] [Related]
16. EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.
Saieg MA; Geddie WR; Boerner SL; Bailey D; Crump M; da Cunha Santos G
Cancer Cytopathol; 2013 Jul; 121(7):377-86. PubMed ID: 23361872
[TBL] [Abstract][Full Text] [Related]
17. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
18. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
19. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.
Hellmuth JC; Louissaint A; Szczepanowski M; Haebe S; Pastore A; Alig S; Staiger AM; Hartmann S; Kridel R; Ducar MD; Koch P; Dreyling M; Hansmann ML; Ott G; Rosenwald A; Gascoyne RD; Weinstock DM; Hiddemann W; Klapper W; Weigert O
Blood; 2018 Oct; 132(16):1695-1702. PubMed ID: 30126979
[TBL] [Abstract][Full Text] [Related]
20. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
